Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Semaglutide and Dapagliflozin in Diabetic Patients With Different Pathophysiology

NCT04451837 is registered in ClinicalTrials.gov with Region Skane as lead sponsor.

NCT NCT04451837
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04451837 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Semaglutide and Dapagliflozin in Diabetic Patients With Different Pathophysiology
Lead sponsor
Region Skane
Phase
Phase 2
Overall status
Active, not recruiting
Start date
September 10, 2020
Completion date
December 31, 2026
Enrollment
200 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

type2 diabetes